

# Vamsi K Kota

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4928797/publications.pdf>

Version: 2024-02-01

93  
papers

1,138  
citations

471061

17  
h-index

476904

29  
g-index

99  
all docs

99  
docs citations

99  
times ranked

1865  
citing authors

#	ARTICLE	IF	CITATIONS
1	Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors. <i>Journal of the National Cancer Institute</i> , 2022, 114, 160-164.	3.0	9
2	Clinical and molecular assessment of an <sc>onco-immune</sc> signature with prognostic significance in patients with colorectal cancer. <i>Cancer Medicine</i> , 2022, 11, 1573-1586.	1.3	6
3	Patient preferences for frontline therapies for Philadelphia chromosome-positive acute lymphoblastic leukemia: a discrete choice experiment. <i>Future Oncology</i> , 2022, , .	1.1	2
4	Clinical validation of a multiplex PCR-based detection assay using saliva or nasopharyngeal samples for SARS-Cov-2, influenza A and B. <i>Scientific Reports</i> , 2022, 12, 3480.	1.6	9
5	PARIS and SPARTA: Finding the Achillesâ€™ Heel of SARS-CoV-2. <i>MSphere</i> , 2022, 7, e0017922.	1.3	25
6	Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. <i>Leukemia</i> , 2022, 36, 1825-1833.	3.3	43
7	Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 669-678.	0.6	10
8	Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia. <i>JAMA Oncology</i> , 2021, 7, 42.	3.4	51
9	Comanagement Strategy Between Academic Institutions and Community Practices to Reduce Induction Mortality in Acute Promyelocytic Leukemia. <i>JCO Oncology Practice</i> , 2021, 17, e497-e505.	1.4	14
10	Immunogenomic Gene Signature of Cell-Death Associated Genes with Prognostic Implications in Lung Cancer. <i>Cancers</i> , 2021, 13, 155.	1.7	38
11	Prognostic and therapeutic implications of extracellular matrix associated gene signature in renal clear cell carcinoma. <i>Scientific Reports</i> , 2021, 11, 7561.	1.6	17
12	Meta-Analysis of Gastrointestinal Adverse Events from Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia. <i>Cancers</i> , 2021, 13, 1643.	1.7	11
13	SalivaSTAT: Direct-PCR and Pooling of Saliva Samples Collected in Healthcare and Community Setting for SARS-CoV-2 Mass Surveillance. <i>Diagnostics</i> , 2021, 11, 904.	1.3	19
14	Clinical Validation of a Sensitive Test for Saliva Collected in Healthcare and Community Settings with Pooling Utility for Severe Acute Respiratory Syndrome Coronavirus 2 Mass Surveillance. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 788-795.	1.2	14
15	Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome-â€™ positive leukemias. <i>Leukemia Research</i> , 2021, 111, 106690.	0.4	12
16	Natural Killer Cells and Dendritic Cells: Expanding Clinical Relevance in the Non-Small Cell Lung Cancer (NSCLC) Tumor Microenvironment. <i>Cancers</i> , 2021, 13, 4037.	1.7	16
17	A Rare Case of Epidural Myeloma Presenting as Recurrent Subdural Bleeding. <i>Cureus</i> , 2021, 13, e17794.	0.2	0
18	Sudden Blast Crisis After Excellent Initial Response in Chronic Myeloid Leukemia. <i>Cureus</i> , 2021, 13, e18368.	0.2	1

#	ARTICLE	IF	CITATIONS
19	Epidemiology, Staging, and Management of Multiple Myeloma. <i>Medical Sciences (Basel, Switzerland)</i> , 2021, 9, 3.	1.3	79
20	Central Line Associated Bloodstream Infection Rate Among Hematologic Malignant Patients Who Received Antimicrobial Prophylaxis in the Inpatient Setting. <i>Blood</i> , 2021, 138, 4390-4390.	0.6	0
21	The Increased Use of Diagnostic Studies over Time in Acute Myelogenous Leukemia Patients. <i>Blood</i> , 2021, 138, 4979-4979.	0.6	0
22	Rates of Neutropenic Fever in Patients with Hematologic Malignant Diseases with Central Venous Access. <i>Blood</i> , 2021, 138, 4953-4953.	0.6	0
23	Serum Albumin As a Prognostic Factor for Overall Survival at 6-Months in Acute Myeloid Leukemia (AML). <i>Blood</i> , 2021, 138, 1226-1226.	0.6	1
24	Clinical performance and utility of a comprehensive next-generation sequencing DNA panel for the simultaneous analysis of variants, TMB and MSI for myeloid neoplasms. <i>PLoS ONE</i> , 2020, 15, e0240976.	1.1	11
25	Management of a 75-Year-Old Lady with Refractory Chronic Myelogenous Leukemia. <i>Case Reports in Oncology</i> , 2020, 13, 534-537.	0.3	1
26	Thyroiditis: A Rare Manifestation of Enasidenib-Induced Differentiation Syndrome. <i>Case Reports in Oncology</i> , 2020, 13, 583-587.	0.3	3
27	Infections of the lung: a predictive, preventive and personalized perspective through the lens of evolution, the emergence of SARS-CoV-2 and its pathogenesis. <i>EPMA Journal</i> , 2020, 11, 581-601.	3.3	11
28	Proposal of RT-PCR-Based Mass Population Screening for Severe Acute Respiratory Syndrome Coronavirus 2 (Coronavirus Disease 2019). <i>Journal of Molecular Diagnostics</i> , 2020, 22, 1294-1299.	1.2	27
29	Long-Term Use of Ruxolitinib in an AML Patient with Posttransplant Steroid Refractory GVHD. <i>Case Reports in Oncological Medicine</i> , 2020, 2020, 1-3.	0.2	2
30	Effective optimization of SARS-CoV-2 laboratory testing variables in an era of supply chain constraints. <i>Future Microbiology</i> , 2020, 15, 1483-1487.	1.0	5
31	Role of indoleamine 2,3-dioxygenase in acute myeloid leukemia. <i>Future Oncology</i> , 2020, 16, 3085-3094.	1.1	3
32	Outcomes of Chronic Phase Chronic Myeloid Leukemia after Treatment with Multiple Tyrosine Kinase Inhibitors. <i>Journal of Clinical Medicine</i> , 2020, 9, 1542.	1.0	5
33	Optimizing management of acute leukemia in community centers and when to refer. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 123-128.	0.9	5
34	A nationwide analysis of outcomes of stroke in hospitalized patients with essential thrombocythemia: 2006 to 2014. <i>American Journal of Blood Research</i> , 2020, 10, 76-81.	0.6	2
35	Analysis of outcomes in hospitalized pregnant patients with acute myeloid leukemia. <i>American Journal of Blood Research</i> , 2020, 10, 68-75.	0.6	1
36	Age and race distribution in patients in phase III oncology clinical trials. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 5977-5983.	0.0	7

#	ARTICLE	IF	CITATIONS
37	Outcomes of hospitalized patients with myocardial infarction and immune thrombocytopenic purpura: a cross sectional study over 15 years. American Journal of Blood Research, 2020, 10, 210-216.	0.6	0
38	Mortality trends in sickle cell patients. American Journal of Blood Research, 2020, 10, 190-197.	0.6	0
39	Trends in the crossover of patients in phase III oncology clinical trials in the USA. Ecancermedicalscience, 2020, 14, 1142.	0.6	1
40	Trends in the crossover of patients in phase III oncology clinical trials in the USA. Ecancermedicalscience, 2020, 14, 1142.	0.6	5
41	Identification and Clinical Validation of a Novel 4 Gene-Signature with Prognostic Utility in Colorectal Cancer. International Journal of Molecular Sciences, 2019, 20, 3818.	1.8	48
42	Availability of all-trans retinoic acid and support systems for management of acute promyelocytic leukemia in Michigan and Louisiana, USA. Hematology Reports, 2019, 11, 7896.	0.3	2
43	Rectovaginal Fistula as a Complication of Fecal Management System. Journal of Investigative Medicine High Impact Case Reports, 2019, 7, 232470961986936.	0.3	1
44	A retrospective study evaluating treatment patterns and survival outcomes in elderly patients with acute myeloid leukemia treated in the United States with either 7+3 or a hypomethylating agent. Leukemia Research, 2019, 78, 45-51.	0.4	13
45	Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Tyrosine Kinase Inhibitor Therapy Cessation. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 480-487.	0.2	11
46	Patients' perspectives on the definition of cure in chronic myeloid leukemia. Leukemia Research, 2019, 80, 40-42.	0.4	4
47	Patient characteristics, treatment patterns, and mortality in elderly patients newly diagnosed with ALL. Leukemia and Lymphoma, 2019, 60, 1462-1468.	0.6	10
48	Tyrosine Kinase Inhibitor Therapy Discontinuation in Clinical Practice in Chronic Myeloid Leukemia - a US Physician Survey Conducted after Guideline Updates. Blood, 2019, 134, 2208-2208.	0.6	3
49	A Case of Chronic Myelogenous Leukemia Occurring in a Patient Treated for Essential Thrombocythemia. American Journal of Case Reports, 2019, 20, 10-14.	0.3	5
50	Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease. Bone Marrow Transplantation, 2018, 53, 826-831.	1.3	69
51	Rhabdomyolysis Following Initiation of Antiviral Therapy with Oseltamivir. American Journal of Case Reports, 2018, 19, 673-677.	0.3	4
52	Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review. Journal of Hematology and Oncology, 2018, 11, 143.	6.9	52
53	Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States. Leukemia Research, 2018, 71, 27-33.	0.4	22
54	Efficacy and Safety Following Dose Reduction of Bosutinib or Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia: Analysis of the Phase 3 BFORE Trial. Blood, 2018, 132, 3005-3005.	0.6	7

#	ARTICLE	IF	CITATIONS
55	Bosutinib or Imatinib in Older Vs Younger Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Phase 3 BFORE Trial. <i>Blood</i> , 2018, 132, 1734-1734.	0.6	5
56	A Nationwide Analysis of Outcomes of Stroke in Hospitalized Patients with Essential Thrombocythemia: 2006 to 2014. <i>Blood</i> , 2018, 132, 4293-4293.	0.6	0
57	Outcomes of Hospitalized Patients with Myocardial Infarction and Immune Thrombocytopenic Purpura: A Cross Sectional Study over 15 Years. <i>Blood</i> , 2018, 132, 4977-4977.	0.6	0
58	Evaluation of romiplostim for the treatment of secondary failure of platelet recovery among allogeneic hematopoietic stem cell transplant patients. <i>Journal of Oncology Pharmacy Practice</i> , 2017, 23, 10-17.	0.5	18
59	Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?. <i>Cancer</i> , 2017, 123, 2482-2488.	2.0	12
60	Rhabdomyolysis Following Initiation of Posaconazole Use for Antifungal Prophylaxis in a Patient With Relapsed Acute Myeloid Leukemia. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2017, 5, 232470961769074.	0.3	2
61	A novel immunohistochemical score to predict early mortality in acute myeloid leukemia patients based on indoleamine 2,3 dioxygenase expression. <i>Scientific Reports</i> , 2017, 7, 12892.	1.6	31
62	Outcomes of Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Following an Elective Switch From Second-Generation Tyrosine Kinase Inhibitor to Imatinib. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e71-e73.	0.2	4
63	The safety of Bosutinib for the treatment of chronic myeloid leukemia. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 1203-1209.	1.0	11
64	Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia. <i>Future Oncology</i> , 2017, 13, 395-407.	1.1	10
65	Managing acute promyelocytic leukemia in patients belonging to the Jehovah's Witness congregation. <i>Hematology Reports</i> , 2017, 9, 7083.	0.3	3
66	Complete Remission of Acute Myeloid Leukemia following Cisplatin Based Concurrent Therapy with Radiation for Squamous Cell Laryngeal Cancer. <i>Case Reports in Hematology</i> , 2016, 2016, 1-4.	0.3	4
67	Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1348-1356.	2.0	76
68	Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 466-471.e1.	0.2	37
69	Recurrent Parotid Carcinosarcoma in an Asymptomatic Patient. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2016, 4, 232470961667659.	0.3	2
70	Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplant. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 416-422.	0.5	5
71	Efficacy and Safety Following Bosutinib Dose Reduction in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia. <i>Blood</i> , 2016, 128, 1921-1921.	0.6	4
72	Prognostic value of complete remission with superior platelet counts in acute myeloid leukemia. <i>Journal of Community and Supportive Oncology</i> , 2016, 14, 66-71.	0.1	4

#	ARTICLE	IF	CITATIONS
73	A Multi-Center Prospective Study Utilizing a Simplified Treatment Algorithm Complemented By Expert Support Decreases Induction Mortality and Improves Survival in Acute Promyelocytic Leukemia (APL). Results of the APL Trial in Georgia, South Carolina and Neighboring States. <i>Blood</i> , 2016, 128, 2793-2793.	0.6	1
74	Acute Facial Paralysis and Otomastoiditis as Presenting Symptoms of Myeloid Sarcoma. <i>Otology and Neurotology</i> , 2015, 36, e104-e106.	0.7	5
75	Volasertib for AML: clinical use and patient consideration. <i>OncoTargets and Therapy</i> , 2015, 8, 1761.	1.0	13
76	Pneumatosis Intestinalis in a Patient with Acute Promyelocytic Leukemia. <i>Case Reports in Hematology</i> , 2015, 2015, 1-3.	0.3	2
77	Predicting early blast transformation in chronic-phase chronic myeloid leukemia: Is immunophenotyping the missing link?. <i>Cancer</i> , 2015, 121, 872-875.	2.0	19
78	Ruxolitinib As Sparing Agent for Steroid-Dependent Chronic Graft-Versus-Host Disease (cGVHD). <i>Blood</i> , 2015, 126, 1938-1938.	0.6	8
79	ATRA Availability on Formulary for the Treatment of APL Across Hospitals in the State of Georgia. <i>Blood</i> , 2015, 126, 4924-4924.	0.6	1
80	Bosutinib: a third generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 765-770.	1.1	9
81	A successful model to decrease early deaths in acute promyelocytic leukemia (APL) through the use of a simplified algorithm and expert support.. <i>Journal of Clinical Oncology</i> , 2014, 32, e18018-e18018.	0.8	1
82	Decreasing early mortality (30-day) in APL patients with use of streamlined treatment guidelines and support from core group of experts.. <i>Journal of Clinical Oncology</i> , 2013, 31, 7091-7091.	0.8	0
83	Congestive heart failure (CHF) in acute myeloid leukemia patients during induction.. <i>Journal of Clinical Oncology</i> , 2013, 31, 7105-7105.	0.8	1
84	A Successful Model To Decrease Early and Preventable Deaths In Acute Promyelocytic Leukemia (APL) Through The Use Of a Simplified Algorithm and Expert Support In Experienced As Well As Smaller Leukemia Treatment Centers In The US. <i>Blood</i> , 2013, 122, 5597-5597.	0.6	1
85	Intermediate-Dose versus Low-Dose Cyclophosphamide and Granulocyte Colony-Stimulating Factor for Peripheral Blood Stem Cell Mobilization in Patients with Multiple Myeloma Treated with Novel Induction Therapies. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1128-1135.	2.0	59
86	miRNA expression profiling of CD20+ plasma cell myeloma (PCM): Upregulation of miR-155 shedding new insight into disease biology and clinicopathologic behavior.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8108-8108.	0.8	0
87	Intermediate-Dose Cyclophosphamide Versus Plerixafor and Granulocyte Colony Stimulating Factor (G-CSF) for Peripheral Blood Progenitor Cell (PBPC) Mobilization in Patients with Multiple Myeloma (MM) Treated with Novel Induction Chemotherapies â€œ A Multicenter Analysis. <i>Blood</i> , 2012, 120, 4409-4409.	0.6	0
88	A Network of Treatment Centers and Standardisation of Treatment Protocol Leads to Reduction in Mortality in Acute Promyelocytic Leukemia (APL). <i>Blood</i> , 2012, 120, 4317-4317.	0.6	40
89	Improving the Accuracy of BCR-ABL Transcript Quantitation: Pitfalls of Using a Common Standard for b3a2 and b2a2 Transcripts. <i>Blood</i> , 2012, 120, 4423-4423.	0.6	0
90	Defining Treatment Paradigms for BK Virus-Induced Hemorrhagic Cystitis in the Post-Allogeneic Hematopoietic Stem Cell Transplant Setting. <i>Blood</i> , 2011, 118, 4468-4468.	0.6	0

#	ARTICLE	IF	CITATIONS
91	Chromosome 7 Abnormalities in Allogeneic Transplantation for AML and MDS. <i>Blood</i> , 2011, 118, 2037-2037.	0.6	1
92	Intermediate- Versus Low-Dose Cyclophosphamide and Granulocyte Colony Stimulating Factor for Peripheral Blood Progenitor Cell Mobilization in Patients with Multiple Myeloma Treated with Novel Induction Chemotherapies â€” A Multicenter Analysis. <i>Blood</i> , 2011, 118, 313-313.	0.6	0
93	Acute leukemia with PICALMâ€™MLLT10 fusion gene: diagnostic and treatment struggle. <i>Cancer Genetics and Cytogenetics</i> , 2010, 202, 129-132.	1.0	21